EGRP News Flash - December 22, 2011

RFAs Reissued for Innovative Molecular Analysis Technologies (IMAT) for Cancer Research

The National Cancer Institute has reissued four Requests for Applications (RFAs) for the Innovative Molecular Analysis Technologies (IMAT) Cancer Program. IMAT's goal is to develop tools and methods that enable cancer researchers to make new discoveries, enhance our understanding of cancer etiology and proliferation, improve detection capabilities, develop diagnostic methods and treatment strategies, conduct large population studies, address and reduce disparities in clinical care, and assist in clinical decision-making.

The Program RFAs support:

  1. Early-Stage Innovative Technology Development for Cancer Research – Exploratory/Developmental Research Grant Awards (R21) – This FOA solicits grant applications proposing exploratory research projects focused on the inception and development of early stage, highly innovative, technologies or emerging technologies with significant transformative potential that have not yet been explored in a cancer-relevant use. An emerging technology is defined (for the purpose of this FOA) as one that has passed the initial developmental stage, but has not yet been evaluated within the context of a cancer-relevant intended use and requires significant modification for the proposed application.

    This FOA's emphasis is on technologies with a high degree of technical innovation and with the potential to significantly affect and transform investigations exploring the molecular and cellular bases of cancer. If successful, these technologies would accelerate and/or enhance research in the areas of cancer biology, prevention, diagnosis and treatment, control, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be based on molecular and/or cellular characterizations of cancer. This RFA is a reissuance of RFA-CA-10-005.

    Letters of intent are due January 23, 2012; April 21, 2012; and August 18, 2012. Applications are due are February 23, 2012; May 21, 2012; and September 18, 2012, by 5 p.m. local time of applicant organization.

    NIH Guide for Grants and Contracts: RFA-CA-12-002External Web Site Policy

  2. Validation and Advanced Development of Emerging Technologies for Cancer Research – Exploratory/Developmental Grants Phase II (R33) – This FOA solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies through technical/analytical validation in an appropriate cancer-relevant biological system or context. An emerging technology is defined as one that has passed the pilot developmental stage and shows promise, but has not yet been evaluated within the context of its intended use. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities.

    This FOA solicits projects where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Proposed projects should reflect the potential to produce a major impact in a broad area of cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation as non-responsive and will not be reviewed. This RFA is a reissuance of RFA-CA-10-004.

    Letters of intent are due January 23, 2012; April 21, 2012; and August 18, 2012. Applications are due February 23, 2012; May 21, 2012; and September 18, 2012, by 5 p.m. local time of applicant organization.

    NIH Guide for Grants and Contracts: RFA-CA-12-003External Web Site Policy

  3. Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science – Exploratory/Developmental Research Grant Award (R21) - This FOA solicits grant applications proposing technically innovative feasibility studies focused on early-stage development of technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of cancer-relevant biospecimens or their derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or samples derived from those biospecimens for downstream molecular analyses.

    This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, prevention, diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen and/or sample quality. All projects must include quantitative milestones (i.e., technical metrics that determine whether the specific aims have been accomplished). This RFA is a reissuance of RFA-CA-10-001.

    Letters of intent are due January 23, 2012; April 21, 2012; and August 18, 2012. Applications are due February 23, 2012; May 21, 2012; and September 18, 2012, by 5 p.m. local time of applicant organization.

    NIH Guide for Grants and Contracts: RFA-CA-12-004External Web Site Policy

  4. Validation and Advanced Development of Emerging Technologies in Biospecimen Science – Exploratory/Developmental Grants Phase (R33) – This FOA solicits grant applications proposing technically innovative feasibility studies focused on the advanced development and validation of cancer-relevant technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or their derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or their derived samples for downstream molecular analyses.

    This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. This RFA is a reissuance of RFA-CA-10-002.

    Letters of intent are due January 23, 2012; April 21, 2012; and August 18, 2012. Applications are due February 23, 2012; May 21, 2012; and September 18, 2012, by 5 p.m. local time of applicant organization.

    NIH Guide for Grants and Contracts: RFA-CA-12-005External Web Site Policy

See also the summary Notice "Innovative Molecular Analysis Technologies (IMAT) for Cancer Research" - Selection of Appropriate Funding Opportunity in the NIH Guide for Grants and Contracts: NOT-CA-006External Web Site Policy

Learn more about the IMAT ProgramExternal Web Site Policy.

For cancer epidemiology questions related to the RFAs described above, contact EGRP's Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch.

Return to Top